Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Coopey on Institutional and Societal Initiatives to Support Women in Oncology

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

Dr Coopey on Addressing Gender Disparities in Cancer Care

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses the importance of addressing gender disparities in cancer care.

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

March 7th 2024

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy

March 7th 2024

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer

March 7th 2024

Eftilagimod alpha in combination with chemotherapy displayed a manageable safety profile in HR+/HER2-low breast cancer.

Standard of Care Regimens for Second-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Laura Spring, MD, and Manali Bhave, MD, discuss findings from the DESTINY-Breast03 trial and how these results have led them to adopt T-DM1 as the new standard of care over lapatinib/capecitabine for second-line treatment of HER2-positive metastatic breast cancer after progression on first-line trastuzumab and a taxane.

Key Clinical Trials in the First-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Oncologists discuss key learnings from clinical trials investigating the first-line treatment of patients with HER2-positive metastatic breast cancer, and how these findings help inform their clinical practice regarding selection of optimal systemic therapy regimens.

Dr Blackwood on the Significance of Early Breast Cancer Screenings

March 5th 2024

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Dr Jagsi on the Implications of the IDEA Trial For Patients With Breast Cancer

March 4th 2024

Reshma Jagsi, MD, DPhil, discusses the implications of the IDEA trial for patients with breast cancer.

EMA Validates MAAs for Datopotamab Deruxtecan in NSCLC and HR+ Breast Cancer

March 4th 2024

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.

Dr Jagsi on the Implications of the IDEA Trial for Radiotherapy Omission in Breast Cancer

March 1st 2024

Reshma Jagsi, MD, Dphil, discusses caveats when interpreting long-term results from the IDEA trial of radiotherapy omission in breast cancer.

Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer Care

March 1st 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer

February 29th 2024

Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.

Dr Wisinski on Treatment Developments in HR+/HER2– Breast Cancer

February 29th 2024

Kari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.

Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer

February 29th 2024

Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.

Ongoing Studies in Genomic Testing for Breast Cancer

February 27th 2024

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Reflecting on Genomic Testing in Practice for Breast Cancer

February 27th 2024

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

February 23rd 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Dr Jagsi on the Feasibility of Radiation Omission Following Surgery in Breast Cancer Care

February 22nd 2024

Reshma Jagsi, MD, DPhil, discusses 5-year findings from the IDEA trial assessing radiotherapy omission for postmenopausal patients with breast cancer.